Literature DB >> 19655191

Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis.

Akiyuki Uzawa, Masahiro Mori, Michihiro Ito, Tomohiko Uchida, Sei Hayakawa, Saeko Masuda, Satoshi Kuwabara.   

Abstract

To investigate differences in helper T cell immune responses in cerebrospinal fluid (CSF) between neuromyelitis optica (NMO) and multiple sclerosis (MS), we measured CSF levels of interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor-a and interferon-c at the time of relapse in 17 NMO patients and 21 MS patients using fluorescence-activated cell sorting. CSF IL-6 levels were significantly higher in NMO patients than in patients with MS (P = 0.001) and other neurological diseases (P = 0.001). The other cytokines tested were undetectable. Elevated CSF levels of IL-6 in only NMO supports the view of different pathophysiologies of NMO and MS. CSF IL-6 levels may be useful in the differential diagnosis of the two disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19655191     DOI: 10.1007/s00415-009-5274-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  The IL-23/IL-17 axis in inflammation.

Authors:  Yoichiro Iwakura; Harumichi Ishigame
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

2.  Brain magnetic resonance imaging findings in relapsing neuromyelitis optica.

Authors:  José A Cabrera-Gómez; L Quevedo-Sotolongo; A González-Quevedo; S Lima; Y Real-González; M Cristófol-Corominas; K Romero-García; C Ugarte-Sánchez; J Jordán-González; J E González de la Nuez; J García Lahera; R Tellez; I Pedroso-Ibañez; R Rodríguez Roca; A Y Cabrera-Núñez
Journal:  Mult Scler       Date:  2007-01-29       Impact factor: 6.312

3.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

4.  Activation of humoral immunity and eosinophils in neuromyelitis optica.

Authors:  Jorge Correale; Marcela Fiol
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

5.  Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis.

Authors:  Takaaki Ishizu; Manabu Osoegawa; Feng-Jun Mei; Hitoshi Kikuchi; Masahito Tanaka; Yuka Takakura; Motozumi Minohara; Hiroyuki Murai; Futoshi Mihara; Takayuki Taniwaki; Jun-ichi Kira
Journal:  Brain       Date:  2005-03-02       Impact factor: 13.501

6.  IL-17 eliminates the therapeutic effects of myelin basic protein-induced nasal tolerance in experimental autoimmune encephalomyelitis by activating IL-6.

Authors:  G-Y Wang; B Sun; Q-F Kong; Y Zhang; R Li; J-H Wang; D-D Wang; G X Lv; H-L Li
Journal:  Scand J Immunol       Date:  2008-12       Impact factor: 3.487

7.  Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay.

Authors:  Sei Hayakawa; Masahiro Mori; Akiko Okuta; Akiko Kamegawa; Yoshinori Fujiyoshi; Yasumasa Yoshiyama; Kaoru Mitsuoka; Kenichi Ishibashi; Sei Sasaki; Takamichi Hattori; Satoshi Kuwabara
Journal:  J Neuroimmunol       Date:  2008-05-06       Impact factor: 3.478

8.  Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

Authors:  Toshiyuki Takahashi; Kazuo Fujihara; Ichiro Nakashima; Tatsuro Misu; Isabelle Miyazawa; Masashi Nakamura; Shohei Watanabe; Yusei Shiga; Chihiro Kanaoka; Juichi Fujimori; Shigeru Sato; Yasuto Itoyama
Journal:  Brain       Date:  2007-04-19       Impact factor: 13.501

9.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  34 in total

Review 1.  Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.

Authors:  Sara J Ireland; Nancy L Monson; Laurie S Davis
Journal:  Cytokine       Date:  2015-03-17       Impact factor: 3.861

Review 2.  Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.

Authors:  Sean J Pittock; Claudia F Lucchinetti
Journal:  Ann N Y Acad Sci       Date:  2015-06-10       Impact factor: 5.691

Review 3.  Immunology of neuromyelitis optica: a T cell-B cell collaboration.

Authors:  Meike Mitsdoerffer; Vijay Kuchroo; Thomas Korn
Journal:  Ann N Y Acad Sci       Date:  2013-04       Impact factor: 5.691

Review 4.  Advances in multiple sclerosis research in 2009.

Authors:  Stefan Nessler; Wolfgang Brück
Journal:  J Neurol       Date:  2010-08-06       Impact factor: 4.849

5.  Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica.

Authors:  Takashi Kageyama; Mika Komori; Katsuichi Miyamoto; Akihiko Ozaki; Toshihiko Suenaga; Ryosuke Takahashi; Susumu Kusunoki; Sadayuki Matsumoto; Takayuki Kondo
Journal:  J Neurol       Date:  2012-10-18       Impact factor: 4.849

Review 6.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

7.  Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.

Authors:  Ilya Ayzenberg; Joanna Schöllhammer; Robert Hoepner; Kerstin Hellwig; Marius Ringelstein; Orhan Aktas; Tania Kümpfel; Markus Krumbholz; Corinna Trebst; Friedemann Paul; Florence Pache; Mark Obermann; Lena Zeltner; Matthias Schwab; Achim Berthele; Sven Jarius; Ingo Kleiter
Journal:  J Neurol       Date:  2016-01-25       Impact factor: 4.849

Review 8.  The treatment of neuromyelitis optica.

Authors:  Markus C Kowarik; John Soltys; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2014-03       Impact factor: 3.042

Review 9.  Pain in neuromyelitis optica--prevalence, pathogenesis and therapy.

Authors:  Monika Bradl; Yoko Kanamori; Ichiro Nakashima; Tatsuro Misu; Kazuo Fujihara; Hans Lassmann; Jürgen Sandkühler
Journal:  Nat Rev Neurol       Date:  2014-07-29       Impact factor: 42.937

Review 10.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.